Pharsight

Genvoya generic

Genvoya is an anti-HIV drug owned by Gilead Sciences Inc. The active ingredients in Genvoya include Cobicistat, Elvitegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate. Genvoya was first authorized for market use on 5th November 2015.

When will Genvoya generic be available?

Potential generic versions of Genvoya can be expected to be released after the 6th of April, 2033, following the expiration of the last patent. This release date of Genvoya generic may be affected by Para IV filings by other companies aiming to manufacture a generic version.

Genvoya uses

Genvoya is primarily used in the treatment of human immunodeficiency virus (HIV) infections. It's composed of a unique composition that contains a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase, which contributes largely to its effectiveness in treating HIV infections.

Genvoya patent expiration

Genvoya is protected by a total of 21 patents, with the last patent expected to expire on the 6th of April, 2033. Among these patents, one has already expired by the first quarter of 2022. This patent protection timeline indicates the earliest possible date for the availability of Genvoya generic. Below are the details of the patents:

EPO Oppostions filed on Genvoya

Litigations filed on Genvoya

Genvoya dosage

Want to ask something?